GlobeNewswire
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
📊
AI Sentiment
Positive
7/10
- Home
- ALXO
as of 02-24-2026 9:32am EST
$2.39
$0.03
-1.24%
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 68.3M | IPO Year: | 2020 |
| Target Price: | $3.42 | AVG Volume (30 days): | 893.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.48 | EPS Growth: | 31.02 |
| 52 Week Low/High: | $0.41 - $2.66 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -1.64 | Index: | N/A |
| Free Cash Flow: | -122359000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of ALX Oncology Holdings Inc. (ALXO)
Pinto Shelly
Sell
SVP, FINANCE AND CAO
ALXO Feb 18, 2026
Avg Cost/Share
$2.27
Shares
565
Total Value
$1,282.55
Owned After
87,708
SEC Form 4
GOODMAN COREY S
Buy
Director, 10% Owner
ALXO Feb 2, 2026
Avg Cost/Share
$1.57
Shares
3,184,713
Total Value
$4,999,999.41
Owned After
8,453,038
SEC Form 4
Pinto Shelly
Sell
SVP, FINANCE AND CAO
ALXO Jan 6, 2026
Avg Cost/Share
$1.11
Shares
3,925
Total Value
$4,356.75
Owned After
87,708
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Pinto Shelly | ALXO | SVP, FINANCE AND CAO | Feb 18, 2026 | Sell | $2.27 | 565 | $1,282.55 | 87,708 | |
| GOODMAN COREY S | ALXO | Director, 10% Owner | Feb 2, 2026 | Buy | $1.57 | 3,184,713 | $4,999,999.41 | 8,453,038 | |
| Pinto Shelly | ALXO | SVP, FINANCE AND CAO | Jan 6, 2026 | Sell | $1.11 | 3,925 | $4,356.75 | 87,708 |
Latest ALX Oncology Holdings Inc. News
ALXO Breaking Stock News: Dive into ALXO Ticker-Specific Updates for Smart Investing
Compare ALXO vs Leading Stocks
See how ALXO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ALXO ALX Oncology Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.